Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

Protein levels were measured in cerebrospinal fluid samples (CSF; n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls. CSF samples and plasma samples were taken from 92 persons with CIS or RRMS at Linköping University Hospital, Sweden and 51 persons with CIS or RRMS at the Karolinska University Hospital, Sweden. Everyone fulfilled the revised McDonald criteria from 2010 and 2017 for CIS or Multiple sclerosis (MS). Age-matched healthy controls (HC) were recruited from healthy blood donors (23 at the Linköping University hospital and 20 at the Karolinska University Hospital). The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins were preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink. Raw data: supplementary information to publication For access to dataset, please contact [e-mail] for further information. Research funders: Swedish Foundation for Strategic Research (SB16-0011) Swedish Brain Foundation Knut and Alice Wallenberg Foundation Margareth AF Ugglas Foundation Swedish Research Council (2019-04193, 2018-02776, 2020-02700, 2021-03092) Swedish Knowledge Foundation (2020-0014) Medical Research Council of Southeast Sweden (FORSS-315121) NEURO Sweden (F2018-0052) ALF grants Region Östergötland Swedish Foundation for MS Research European Union's Marie Sklodowska-Curie (813863) The dataset was originally published in DiVA and moved to SND in 2024.